精氨酸加压素缺乏症患者的骨转换标志物研究
本研究为URANOS试验的二次分析,纳入46名参与者(健康对照22例、AVP-D 11例、原发性多饮13例),评估骨吸收标志物CTX和骨形成标志物P1NP。结果显示AVP-D患者CTX水平低于健康对照,骨形成指数(P1NP/CTX)高于健康对照,但与原发性多饮组无差异。结论不支持AVP-D存在有害的骨代谢改变。
要点
- AVP-D患者CTX水平低于健康对照,骨形成指数升高。
- AVP-D与原发性多饮组间骨转换标志物无显著差异。
- AVP-D患者25OH-维生素D水平低于健康对照。
核心结论
- AVP-D患者CTX水平降低、P1NP/CTX比值升高,但未发现重大有害骨代谢改变。
研究设计与样本
- 前瞻性URANOS试验(NCT05890690)的二次分析,2023年6月至2024年6月,纳入46例参与者(健康对照22例、AVP-D 11例、原发性多饮13例)。
主要发现
- 血清钙、磷、P1NP水平在各组间相当。
临床怎么用
- AVP-D患者骨转换标志物改变不提示明显有害骨代谢效应,常规骨代谢评估仍需结合维生素D状态。
局限性
- 样本量小(AVP-D仅11例),为二次分析,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Arginine vasopressin (AVP) and oxytocin are neurohormones with opposing effects on bone in preclinical models, while their relevance in humans remains uncertain. Data on bone metabolism in individuals lacking AVP release-and possibly also oxytocin-such as patients with AVP deficiency (AVP-D, also known as central diabetes insipidus) remain scarce, although the limited available evidence suggests a potentially deleterious effect. OBJECTIVE: This study aimed to evaluate bone turnover markers in patients with AVP-D compared to individuals with primary polydipsia (PP) and healthy controls (HC). METHODS: This was a secondary analysis of the prospective URANOS Trial (NCT05890690) conducted from June 2023 to June 2024. After excluding patients on chronic steroid therapy (except budesonide and replacement therapy), prior osteoporotic fractures, long-term antiresorptive treatment, or medications known to adversely affect bone metabolism (eg, aromatase inhibitors), 46 participants were included (HC = 22, AVP-D = 11, PP = 13). All individuals were assessed for bone resorption (C-terminal telopeptide of type I collagen [CTX]) and bone formation (N-terminal propeptide of type I collagen [P1NP]) markers, as well as 25OH-vitamin D, serum calcium, and phosphate. The bone formation index (defined as P1NP/CTX ratio) was calculated. RESULTS: Serum calcium, phosphate, and P1NP levels were comparable across groups, whereas 25OH-vitamin D concentrations were lower in patients with AVP-D than in HC (P = .031). Median CTX levels were lower in AVP-D (0.373 [0.288-0.513] ng/mL) than in HC (0.592 [0.427-0.729] ng/mL, P = .021), with no difference between PP (0.514 [0.411-0.618] ng/mL) and the other groups. The bone formation index was higher in AVP-D than in HC (P = .036), whereas no difference was observed between PP and either group. In the multivariable linear regression model adjusted for confounders, CTX was lower in AVP-D compared to HC (-0.183; 95% CI, -0.352 to -0.013; P = .036), with no difference compared to PP. CONCLUSION: Patients with AVP-D showed reduced CTX levels and consequently an increased P1NP/CTX ratio compared to HC, whereas no difference was observed between patients with PP and both groups. Overall, these findings do not support major bone metabolic alterations with detrimental effects in AVP-D.
引用
- Varaldo E, Lustenberger S, Atila C, et al. Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls. J Clin Endocrinol Metab. 2026. PMID: 41499390. doi:10.1210/clinem/dgag001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。